Yukai Zhou

Dr. Yukai Zhou

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2024 in Postgraduate Medical Journal
Verified
Journal Article
Closed access
PDF file
RZRui Zhou
Rui Zhou
YCYuansheng Cao
Yuansheng Cao
XCXuemeng Chen
Xuemeng Chen
YPYanhua Peng
Yanhua Peng
CXChao Xiong
Chao Xiong
LXLize Xiong
Lize Xiong
To compare the speed of achieving painless uterine contractions in parturients undergoing epidural analgesia at different lumbar puncture levels. This study is a randomized controlled trial at a tertiary A hospital with a history of over 80 years in Sichuan Province, China. Parturients aged 22–40 years old scheduled for vaginal delivery under epidural analgesia were recruited. Eligible patients were randomly allocated into lumbar 2-3 (L2-3) or lumbar 3-4 (L3-4) groups. Epidural analgesia was performed through the interspaces according to grouping. The primary outcome was the percentage of painless uterine contractions 15 min after the initiation of analgesia. The secondary outcomes included the percentage of painless status at 5 and 10 min, sensory block plane, motor block evaluation, adverse events of parturients, epidural analgesic consumption, Apgar score, and the parturients' evaluation of analgesia. Between April 2023 and August 2023, a total of 150 women were finally recruited, and 136 of them were analyzed (68 in each group). In comparison with the L3-4 groups, there was a significantly larger proportion of painless uterine contractions at 5, 10, and 15 min after analgesia initiation in the L2-3 group (20.6% vs. 7.4%, 52.9% vs. 26.5%, and 80.9% vs. 64.7%, P = .026, .002, and .034, respectively). Similarly, the pain scores were lower in the L2-3 group at 5, 10, and 15 min than that in the L3-4 group (5(4,7) vs. 6(5,7), 3(2,5) vs. 4(3,6), and 2(1,3) vs. 3(2,5), P = .006, .004, and .020, respectively). Furthermore, puncturing through the L2-3 interspace contributed to a higher evaluation of parturients to the analgesia procedure (9(8,9) vs. 8(8,9), P < .001). However, there was no significant difference in sensory block, motor block, or adverse events between the two groups. Puncturing through the L2-3 interspace is associated with faster pain relief and a better experience for parturients. These findings present a superior option for anesthesiologists when conducting epidural labor analgesia. What is already known on this topic? Epidural analgesia is an effective way to relieve labor pain. What this study adds? Puncturing via lumbar 2-3 interspace induces more rapid onset of epidural analgesia. How this study might affect research, practice or policy? Lumbar 2-3 interspace is a superior option in terms of the speed of pain relief and satisfaction of parturients when conducting epidural labor analgesia.

12 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
WJWencai Jiang
Wencai Jiang
YPYanhua Peng
Yanhua Peng
XCXuemeng Chen
Xuemeng Chen
LFLijuan Fu
Lijuan Fu
WZWenhu Zhai
Wenhu Zhai
YZYukai Zhou
Yukai Zhou
Background: Supraclavicular brachial plexus block (SCB) is a common regional analgesic technique for upper limb fracture surgery, but it often leads to rebound pain. Our primary aim is to determine whether different administration methods of esketamine can reduce rebound pain in patients undergoing SCB for upper limb fracture surgery. Methods/design: This study is designed as a single-centre, double-blinded, prospective, randomised controlled trial. Patients undergoing upper limb fracture surgery, who plan to use a tourniquet, aged 18–60 years, with a body mass index of 18–30 kg/m 2 and an American Society of Anaesthesiologists classification of I–III will be randomised into three groups after providing written informed consent: group N (perineural esketamine/ropivacaine); group V (intravenous esketamine/perineural ropivacaine); and group C (perineural ropivacaine). The primary outcome will be the percentage of patients experiencing rebound pain within 24 hours postoperatively. Secondary outcomes include the Numeric Rating Scale (NRS) score of rebound pain, the onset of rebound pain, (since performing SCB), the cumulative area under the curve of NRS pain severity scores through 48 hours postsurgery, postoperative opioid consumption at 48 hours postoperatively, onset and duration of the sensory blockade, onset and duration of the motor blockade and adverse reactions and adverse events. Patients will be followed-up to 48 hours postoperatively. Discussions: This protocol describes the design of a randomised controlled trial to evaluate the effect of different modes of administration of esketamine combined with SCB on the incidence of rebound pain after upper limb fracture surgery. The results may help to identify the most effective methods for managing pain in patients undergoing upper limb fracture surgery. Ethics and dissemination: This study has been approved by the Ethics Committee of the Deyang People’s Hospital (2023-03-010-K01). It was registered on the Chinese Clinical Trials Registry on 24 August 2023. We intend to publish the results in a peer-reviewed journal. Trial registration number: ChiCTR2300075083.

20 April 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
YZYukai Zhou
Yukai Zhou
WWWenzhi Wu
Wenzhi Wu
YZYi Zhang
Yi Zhang
YPYanhua Peng
Yanhua Peng
WJWencai Jiang
Wencai Jiang
AXAn Xie
An Xie
Introduction: Remimazolam, an ultra-short-acting benzodiazepine metabolized by carboxylesterase-1 (CES1), permits specific antagonism by flumazenil, enabling active reversal unavailable with propofol-based sedation. However, the safety profile of this reversal strategy-including re-sedation risk, seizure concerns, and special population considerations-remains incompletely characterized. Methods: This narrative review synthesizes evidence from randomized controlled trials, meta-analyses, pharmacokinetic-pharmacodynamic modeling studies, and pharmacogenomic research identified through comprehensive searches of PubMed, Embase, the Cochrane Library, and Google Scholar through February 2026 to evaluate the clinical utility and safety considerations of flumazenil reversal in remimazolam-based anesthesia. Results: Recent meta-analyses demonstrate that remimazolam-flumazenil accelerates emergence by approximately 4 min versus propofol with significant reductions in respiratory depression (RR 0.41; 95% CI 0.30–0.56) and hypotension (RR 0.25; 95% CI 0.12–0.52), though substantial heterogeneity ( I 2 = 96%) limits pooled estimate precision. Re-sedation occurs in 2–22% of cases depending on procedural duration and outcome definitions, with this variability primarily reflecting heterogeneous procedural settings and inconsistent outcome definitions rather than pharmacogenomic factors. The pharmacogenomics of CES1, particularly the G143E loss-of-function polymorphism, represents an emerging area that may influence remimazolam metabolism and reversal kinetics. Reconciliation of surgical database evidence with elevated pharmacovigilance signals from FAERS analysis suggests confounding by indication in emergency settings; however, the intrinsic neurophysiological risks of rapid GABA-A receptor de-occupation warrant continued vigilance. The Dextran 40 excipient in remimazolam besylate formulations is contraindicated in patients with severe dextran hypersensitivity, and clinicians should consider non-benzodiazepine etiologies when hemodynamic deterioration does not respond to flumazenil. In neonates, immature CES1 activity combined with reduced renal clearance creates theoretical risk of metabolite accumulation, contraindicating use outside research settings. Discussion: This review identifies critical evidence gaps—including the need for standardized re-sedation definitions, prospective validation of pharmacokinetic-pharmacodynamic models, and pediatric pharmacokinetic data—and provides evidence-based considerations for clinical practice while emphasizing the need for systematic review methodology and expert consensus to develop formal clinical guidelines.